Navigation Links
InterMune Reports Results from Triple Combination Study of ITMN-191
Date:1/12/2009

- Q12h and Q8h Regimens Deliver Robust Antiviral Effects and Strong Safety Profile -

- Phase2b Study Anticipated to Begin in Q2 2009 -

- Conference call today at 8:30 a.m. EST -

BRISBANE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today reported top-line results from all six completed dosage cohorts of its Phase 1b clinical trial of ITMN-191 (R7227) in combination with standard-of-care Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) for 14 days of treatment in hepatitis C virus (HCV) treatment-naive patients infected with HCV genotype 1. ITMN-191 is being developed in collaboration with Roche (SWX: ROG). Viral kinetic performance and safety results were reported for three cohorts each of ITMN-191 given every 12 hours (q12h) and every eight hours (q8h).

Viral Kinetic Performance

After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 logs in five of the six cohorts and was -5.4 log and -5.7 log in the best performing q12h and q8h cohorts, respectively. Considering all cohorts, HCV RNA was below the limit of quantification in nearly three-quarters (71%, or 32 of 45) of patients who received treatment with ITMN-191 after only 14 days of treatment. In all q12h and q8h cohorts, reductions in HCV RNA occurred rapidly and there was no evidence of viral rebound during ITMN-191 treatment.

Safety and Tolerability Profile

ITMN-191 was generally safe and well tolerated. There were no serious adverse events (SAE) or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the well-described AE profile of standard of care
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. InterMune to Present at Thomas Weisel Partners Healthcare Conference
2. Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations
3. InterMune to Present at the 2008 Wachovia Healthcare Conference
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
6. Allscripts Reports Fiscal 2009 Second Quarter Results
7. MDS Reports Final Fourth-Quarter 2008 Results
8. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
9. Cardium Reports on Exchange Listing With NYSE Alternext US
10. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
11. Joint Commission Reports Positive Survey Results for CHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Park, NJ (PRWEB) , ... August 03, 2015 ... ... pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” ... software architects, engineers and technology leaders from healthcare organizations with access to the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... ... , ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing ... years of suffering and using medications with strong side effects. This had already forced ... time off or wait longer hours in the waiting rooms. Instead, he went home ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... a leading provider of medical information, risk management and investigative services, has ... and direction toward focused, expert information solutions that improve business outcomes for ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... named Jim Bohnsack vice,president of healthcare information solutions, a ... in the Western region of the United States. , ... president of healthcare,for TransUnion. , ... relationships,with key supporting institutions and organizations will be an ...
... will see Japan,s Trinity Design Corporation Ltd, becoming a reseller and ... already negotiated its first Rhapsody sale with the Kobe Circulation Clinic, ... quality medical care. , ... Auckland, NZ (PRWEB) ...
... LLP, founded in 1968, has successfully represented victims of negligence, personal ... , ... (PRWEB) January 6, 2008 -- Smiley & ... personal injury, wrongful death and medical malpractice for over 40 years. ...
... knew there had to be a better way. He and ... how best to engage patients with chronic diseases in effective ... Chronic Care Model. More than 1,500 U.S. and international medical ... evidence on how the Model performs in practice confirms that ...
... Technology Company today announces the award of a network IP-Based ... ... Washington, D.C. (PRWEB) December 15, 2008 -- ... Notification Technology Company, today announces the award of a network ...
... and surgeon medical liability, launched its first Southeast Legal Summit ... have the most current information regarding the defense of medical ... ... California (Vocus) December 17, 2008--- The Doctors Company , ...
Cached Medicine News:Health News:TransUnion Names New Vice President of Healthcare Information Solutions 2Health News:Orion Health Signs Trinity Design for Japanese Market 2Health News:Orion Health Signs Trinity Design for Japanese Market 3Health News:Prominent New York City Personal Injury Law Firm Founded in 1968 Stays at the Cutting Edge with Launch of Video-Based Website 2Health News:Chronic Care Model helps improve people’s health and care 2Health News:Chronic Care Model helps improve people’s health and care 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 2Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 4Health News:The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians 2
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Shire plc (LSE: SHP, NASDAQ: SHPGY ... on the approval status and availability of ProAmatine® (midodrine ... orthostatic hypotension (SOH).  Shire has engaged in consistent dialogue ... the past 12 months in the hopes of either ...
... ideas are coming out of the small, island nation of ... Unit says for a country of its size, New Zealand ... "New Zealanders are known for their ingenuity—especially in creating ... push the envelope," says Marta Mager, Regional Director Americas for ...
Cached Medicine Technology:Shire Provides Update on ProAmatine® (midodrine HCl) 2Shire Provides Update on ProAmatine® (midodrine HCl) 3Shire Provides Update on ProAmatine® (midodrine HCl) 4Cool New Zealand Inventions 2Cool New Zealand Inventions 3
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... for molecular screening that improves resolution of small ... are:, High resolution of PCR and DNA ... of the gel, enhancing visibility. , Better handling ... structure and higher gel strength. The chances of ...
... Molecular Biology Grade, is used ... nucleic acids. It can be ... from 0.2 to 40 kb., ... is tested and certified to ...
Inquire...
Medicine Products: